Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
复制标题
DOI：
10.1182/blood-2017-09-801498
复制
发表时间：
2018-03-22
期刊：
影响因子：
20.3
通讯作者：
Ossenkoppele, Gert J.
中科院分区：
文献类型：
--
作者：
Schuurhuis, Gerrit J.;Heuser, Michael;Ossenkoppele, Gert J.
可测量残留病（MRD;以前称为微小残留病）是急性髓性白血病（AML）的一个独立的诊断后预后指标，结合诊断时评估的其他成熟的临床、细胞遗传学和分子学数据，对风险分层和治疗计划非常重要。MRD可以使用多种多参数流式细胞术和分子方案进行评估，但迄今为止，这些方法尚未定性或定量标准化，使其在临床实践中的应用具有挑战性。这项工作的目的是确定MRD在AML中的测量和应用中的关键临床和科学问题，就这些问题达成共识，并为当前和未来在临床实践中使用MRD提供指南。这项工作由欧洲白血病网络特别指定的MRD工作组在2年多的4次会议期间完成。该小组包括来自欧洲和美国19个机构的24名在AML血液病理学，分子诊断，临床试验和临床医学方面具有专业知识的教师。
Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, post-diagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.